MCID: RRH023
MIFTS: 41

Rare Hereditary Hemochromatosis

Categories: Cardiovascular diseases, Endocrine diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Rare Hereditary Hemochromatosis

MalaCards integrated aliases for Rare Hereditary Hemochromatosis:

Name: Rare Hereditary Hemochromatosis 58
Iron Overload 54 6 39
Iron Overload Disease 58

Characteristics:

Orphanet epidemiological data:

58
rare hereditary hemochromatosis
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare hepatic diseases
Inborn errors of metabolism


External Ids:

ICD10 via Orphanet 33 E83.1
UMLS via Orphanet 72 C0018995 C0282193
Orphanet 58 ORPHA220489

Summaries for Rare Hereditary Hemochromatosis

MalaCards based summary : Rare Hereditary Hemochromatosis, also known as iron overload, is related to iron overload in africa and hypochromic microcytic anemia with iron overload. The drugs Hyaluronic acid and Sofosbuvir have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and heart, and related phenotypes are joint stiffness and fatigue

Related Diseases for Rare Hereditary Hemochromatosis

Diseases in the Rare Hereditary Hemochromatosis family:

Hemochromatosis, Type 1 Hemochromatosis, Type 2a
Hemochromatosis, Type 3 Hemochromatosis, Type 4
Hemochromatosis, Type 2b Hemochromatosis, Type 5
Hemochromatosis Type 2 Tfr2-Related Hereditary Hemochromatosis

Diseases related to Rare Hereditary Hemochromatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 448, show less)
# Related Disease Score Top Affiliating Genes
1 iron overload in africa 13.1
2 hypochromic microcytic anemia with iron overload 12.9
3 anemia, hypochromic microcytic, with iron overload 1 12.9
4 anemia, hypochromic microcytic, with iron overload 2 12.8
5 genetic hyperferritinemia without iron overload 12.6
6 hemochromatosis, type 5 12.5
7 hemochromatosis, type 4 12.0
8 atransferrinemia 11.9
9 hemochromatosis, type 3 11.9
10 congenital dyserythropoietic anemia 11.9
11 anemia, congenital dyserythropoietic, type ii 11.9
12 anemia, sideroblastic, 1 11.9
13 porphyria cutanea tarda 11.8
14 hyperferritinemia with or without cataract 11.8
15 anemia, sideroblastic, 3, pyridoxine-refractory 11.8
16 ferro-cerebro-cutaneous syndrome 11.7
17 hemochromatosis, type 2a 11.7
18 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 11.7
19 hypochromic microcytic anemia 11.6
20 variegate porphyria 11.6
21 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 11.6
22 anemia, sideroblastic, and spinocerebellar ataxia 11.6
23 anemia, congenital dyserythropoietic, type ia 11.6
24 overhydrated hereditary stomatocytosis 11.5
25 hemochromatosis type 2 11.5
26 zellweger syndrome 11.4
27 anemia, sideroblastic, 4 11.3
28 anemia, sideroblastic, 2, pyridoxine-refractory 11.3
29 pyridoxine-responsive sideroblastic anemia 11.3
30 myelodysplastic syndrome 10.9
31 siderosis 10.8
32 liver disease 10.8
33 deficiency anemia 10.7
34 hemosiderosis 10.7
35 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.7
36 atrial standstill 1 10.6
37 porphyria 10.6
38 fatty liver disease 10.6
39 sickle cell anemia 10.6
40 aplastic anemia 10.5
41 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.5
42 sideroblastic anemia 10.5
43 hemolytic anemia 10.5
44 viral hepatitis 10.5
45 hepatocellular carcinoma 10.5
46 non-alcoholic fatty liver disease 10.5
47 arthropathy 10.5
48 graft-versus-host disease 10.5
49 hypothyroidism 10.5
50 hepatitis c virus 10.5
51 fatty liver disease, nonalcoholic 1 10.4
52 non-alcoholic steatohepatitis 10.4
53 granulocytopenia 10.4
54 hemochromatosis, type 1 10.4
55 leukemia, acute myeloid 10.4
56 refractory anemia 10.4
57 iron deficiency anemia 10.4
58 end stage renal disease 10.4
59 exanthem 10.4
60 microcytic anemia 10.4
61 neutropenia 10.4
62 acute leukemia 10.4
63 splenomegaly 10.4
64 myeloid leukemia 10.4
65 tfr2-related hereditary hemochromatosis 10.4
66 thalassemia 10.3
67 myelofibrosis 10.3
68 pyruvate kinase deficiency of red cells 10.3
69 bone disease 10.3
70 congestive heart failure 10.3
71 osteoporosis 10.3
72 bone mineral density quantitative trait locus 8 10.3
73 bone mineral density quantitative trait locus 15 10.3
74 bone resorption disease 10.3
75 hypoparathyroidism 10.3
76 cataract 10.3
77 mucormycosis 10.3
78 hepatic veno-occlusive disease 10.3
79 endometriosis 10.3
80 atherosclerosis susceptibility 10.2
81 fibrosis of extraocular muscles, congenital, 1 10.2
82 hypercholesterolemia, familial, 1 10.2
83 proteasome-associated autoinflammatory syndrome 1 10.2
84 microvascular complications of diabetes 7 10.2
85 pulmonary hypertension 10.2
86 bacterial infectious disease 10.2
87 hereditary spherocytosis 10.2
88 pure red-cell aplasia 10.2
89 cholestasis 10.2
90 amenorrhea 10.2
91 impotence 10.2
92 chronic graft versus host disease 10.2
93 red cell aplasia 10.2
94 beta-thalassemia 10.2
95 leukemia, acute lymphoblastic 10.2
96 hypogonadotropic hypogonadism 10.2
97 hyperinsulinism 10.2
98 hemoglobin e disease 10.2
99 kidney disease 10.2
100 acute graft versus host disease 10.2
101 alzheimer disease 10.2
102 friedreich ataxia 10.2
103 macular degeneration, age-related, 1 10.2
104 alpha-thalassemia 10.2
105 listeriosis 10.2
106 diarrhea 10.2
107 hepatitis 10.2
108 myopathy 10.2
109 pituitary gland disease 10.2
110 retinal degeneration 10.2
111 aregenerative anemia 10.2
112 alcohol dependence 10.1
113 hemoglobin h disease 10.1
114 transferrin serum level quantitative trait locus 2 10.1
115 mucositis 10.1
116 portal hypertension 10.1
117 leukemia 10.1
118 dilated cardiomyopathy 10.1
119 autoimmune hepatitis 10.1
120 hyperglycemia 10.1
121 adenoma 10.1
122 47,xyy 10.1
123 vibrio vulnificus infection 10.1
124 brain injury 10.1
125 iron metabolism disease 10.1
126 hypertriglyceridemia, familial 10.0
127 dowling-degos disease 1 10.0
128 anemia, autoimmune hemolytic 10.0
129 fanconi anemia, complementation group a 10.0
130 neurodegeneration with brain iron accumulation 1 10.0
131 hypoascorbemia 10.0
132 microvascular complications of diabetes 5 10.0
133 osteomalacia 10.0
134 rickets 10.0
135 alcoholic hepatitis 10.0
136 pancytopenia 10.0
137 hyperparathyroidism 10.0
138 toxic shock syndrome 10.0
139 hepatitis b 10.0
140 benign mesothelioma 10.0
141 bilirubin metabolic disorder 10.0
142 adenocarcinoma 10.0
143 lipid metabolism disorder 10.0
144 uremia 10.0
145 brain edema 10.0
146 retinal disease 10.0
147 congenital hemolytic anemia 10.0
148 hypersplenism 10.0
149 neuroblastoma 10.0
150 chronic kidney disease 10.0
151 peritonitis 10.0
152 diabetes mellitus 10.0
153 48,xyyy 10.0
154 cryptogenic cirrhosis 10.0
155 spinal cord injury 10.0
156 ataxia and polyneuropathy, adult-onset 10.0
157 gracile syndrome 10.0
158 aceruloplasminemia 10.0
159 lactic acidosis 10.0
160 aminoaciduria 10.0
161 spondyloarthropathy 1 10.0
162 arteries, anomalies of 10.0
163 autoimmune disease 10.0
164 diabetes mellitus, noninsulin-dependent 10.0
165 multiple sclerosis 10.0
166 hypertension, essential 10.0
167 mesothelioma, malignant 10.0
168 ovarian cancer 10.0
169 porphyria cutanea tarda, type i 10.0
170 spherocytosis, type 1 10.0
171 triiodothyronine receptor auxiliary protein 10.0
172 hydrops fetalis, nonimmune 10.0
173 myeloma, multiple 10.0
174 wilson disease 10.0
175 yemenite deaf-blind hypopigmentation syndrome 10.0
176 abdominal obesity-metabolic syndrome 1 10.0
177 neurodegeneration with brain iron accumulation 3 10.0
178 coronary heart disease 1 10.0
179 microvascular complications of diabetes 3 10.0
180 microvascular complications of diabetes 4 10.0
181 microvascular complications of diabetes 6 10.0
182 alpha-1-antitrypsin deficiency 10.0
183 aspergillosis 10.0
184 lung disease, immunodeficiency, and chromosome breakage syndrome 10.0
185 hyperlipoproteinemia, type iii 10.0
186 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
187 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0
188 lipoprotein quantitative trait locus 10.0
189 invasive aspergillosis 10.0
190 atrioventricular block 10.0
191 hepatocellular adenoma 10.0
192 cardiac arrest 10.0
193 meningoencephalitis 10.0
194 pre-eclampsia 10.0
195 glucose intolerance 10.0
196 heart disease 10.0
197 chondrocalcinosis 10.0
198 cryptococcosis 10.0
199 inflammatory spondylopathy 10.0
200 primary biliary cirrhosis 10.0
201 cutaneous porphyria 10.0
202 squamous cell papilloma 10.0
203 candidiasis 10.0
204 papilloma 10.0
205 glucosephosphate dehydrogenase deficiency 10.0
206 glomerulonephritis 10.0
207 osteitis fibrosa 10.0
208 bone inflammation disease 10.0
209 plague 10.0
210 calciphylaxis 10.0
211 peripheral nervous system disease 10.0
212 spondylitis 10.0
213 neuropathy 10.0
214 hypoglycemia 10.0
215 allergic encephalomyelitis 10.0
216 cytokine deficiency 10.0
217 growth hormone deficiency 10.0
218 hypoxia 10.0
219 tremor 10.0
220 rapidly involuting congenital hemangioma 10.0
221 argyria 10.0
222 hemochromatosis, neonatal 9.9
223 autosomal recessive disease 9.9
224 diamond-blackfan anemia 9.9
225 alcohol use disorder 9.9
226 hepatitis c 9.9
227 hypogonadism 9.9
228 hemoglobinopathy 9.9
229 movement disease 9.9
230 liver cirrhosis 9.9
231 viral infectious disease 9.9
232 sickle cell disease 9.9
233 cytomegalovirus infection 9.9
234 aortic aneurysm, familial abdominal, 1 9.8
235 amyotrophic lateral sclerosis 1 9.8
236 colorectal cancer 9.8
237 cardiac arrhythmia 9.8
238 cardiac conduction defect 9.8
239 major affective disorder 1 9.8
240 hirschsprung disease 1 9.8
241 huntington disease 9.8
242 endosteal hyperostosis, autosomal dominant 9.8
243 leukemia, chronic lymphocytic 9.8
244 chromosome 5q deletion syndrome 9.8
245 optic atrophy 1 9.8
246 platelet membrane fluidity 9.8
247 protoporphyria, erythropoietic, 1 9.8
248 pulmonary hemosiderosis 9.8
249 sarcoidosis 1 9.8
250 thrombophilia due to activated protein c resistance 9.8
251 down syndrome 9.8
252 tuberous sclerosis 1 9.8
253 iron-refractory iron deficiency anemia 9.8
254 celiac disease 1 9.8
255 chondrodysplasia punctata syndrome 9.8
256 enterocolitis 9.8
257 gaucher disease, type i 9.8
258 dubin-johnson syndrome 9.8
259 hyperbilirubinemia, shunt, primary 9.8
260 cartilage-hair hypoplasia 9.8
261 mitochondrial dna depletion syndrome 3 9.8
262 porphyria, congenital erythropoietic 9.8
263 renal tubular dysgenesis 9.8
264 tyrosinemia, type i 9.8
265 protoporphyria, erythropoietic, x-linked 9.8
266 multiple congenital anomalies-hypotonia-seizures syndrome 2 9.8
267 stroke, ischemic 9.8
268 acute insulin response 9.8
269 branchiootic syndrome 1 9.8
270 generalized epilepsy with febrile seizures plus, type 1 9.8
271 generalized epilepsy with febrile seizures plus, type 2 9.8
272 body mass index quantitative trait locus 1 9.8
273 dyskinesia, familial, with facial myokymia 9.8
274 pulmonary disease, chronic obstructive 9.8
275 febrile seizures, familial, 8 9.8
276 kala-azar 1 9.8
277 leukemia, chronic myeloid 9.8
278 generalized epilepsy with febrile seizures plus, type 4 9.8
279 malaria 9.8
280 diabetes mellitus, ketosis-prone 9.8
281 generalized epilepsy with febrile seizures plus, type 6 9.8
282 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 9.8
283 epilepsy, idiopathic generalized 10 9.8
284 cholangitis, primary sclerosing 9.8
285 generalized epilepsy with febrile seizures plus, type 8 9.8
286 generalized epilepsy with febrile seizures plus, type 7 9.8
287 heme oxygenase 1 deficiency 9.8
288 membranous nephropathy 9.8
289 generalized epilepsy with febrile seizures plus, type 9 9.8
290 hyperproinsulinemia 9.8
291 chorea, childhood-onset, with psychomotor retardation 9.8
292 retinitis pigmentosa and erythrocytic microcytosis 9.8
293 helix syndrome 9.8
294 erythrocytosis, familial, 6 9.8
295 generalized epilepsy with febrile seizures plus, type 10 9.8
296 angiosarcoma 9.8
297 hemophagocytic lymphohistiocytosis 9.8
298 restless legs syndrome 9.8
299 hyperphosphatemia 9.8
300 adult t-cell leukemia 9.8
301 inflammatory bowel disease 9.8
302 rheumatic heart disease 9.8
303 sleep apnea 9.8
304 atrial fibrillation 9.8
305 ptosis 9.8
306 x-linked chondrodysplasia punctata 1 9.8
307 thrombosis 9.8
308 chronic myelomonocytic leukemia 9.8
309 neurodegeneration with brain iron accumulation 9.8
310 asbestosis 9.8
311 interstitial nephritis 9.8
312 hydrocephalus 9.8
313 placenta praevia 9.8
314 sarcoma 9.8
315 cholecystolithiasis 9.8
316 vitamin k deficiency bleeding 9.8
317 adult respiratory distress syndrome 9.8
318 endometriosis of ovary 9.8
319 hemopericardium 9.8
320 cardiac tamponade 9.8
321 infant gynecomastia 9.8
322 polycystic ovary syndrome 9.8
323 choledocholithiasis 9.8
324 pericardial effusion 9.8
325 esophagitis 9.8
326 hypertrophic cardiomyopathy 9.8
327 chagas disease 9.8
328 common variable immunodeficiency 9.8
329 spinal muscular atrophy 9.8
330 secondary hyperparathyroidism 9.8
331 gynecomastia 9.8
332 choreatic disease 9.8
333 acute cystitis 9.8
334 typhoid fever 9.8
335 tuberous sclerosis 9.8
336 eclampsia 9.8
337 obstructive jaundice 9.8
338 biliary atresia 9.8
339 clonorchiasis 9.8
340 polyneuropathy 9.8
341 sclerosing cholangitis 9.8
342 acute chest syndrome 9.8
343 thrombocytopenia 9.8
344 duodenal ulcer 9.8
345 mitral valve stenosis 9.8
346 epilepsy 9.8
347 gaucher's disease 9.8
348 hypothalamic disease 9.8
349 cholecystitis 9.8
350 hepatitis d 9.8
351 intestinal perforation 9.8
352 myeloproliferative neoplasm 9.8
353 lateral sclerosis 9.8
354 colon adenocarcinoma 9.8
355 macrocytic anemia 9.8
356 thrombophilia 9.8
357 motor peripheral neuropathy 9.8
358 sensory peripheral neuropathy 9.8
359 hematologic cancer 9.8
360 hemangioma 9.8
361 kidney cancer 9.8
362 bronchiolitis obliterans 9.8
363 long qt syndrome 9.8
364 bronchiolitis 9.8
365 acute kidney failure 9.8
366 interstitial lung disease 9.8
367 demyelinating disease 9.8
368 ischemia 9.8
369 purpura 9.8
370 aortic aneurysm 9.8
371 restrictive cardiomyopathy 9.8
372 syphilis 9.8
373 rh isoimmunization 9.8
374 spindle cell sarcoma 9.8
375 pancreatitis 9.8
376 infertility 9.8
377 human immunodeficiency virus infectious disease 9.8
378 pneumonia 9.8
379 t-cell adult acute lymphocytic leukemia 9.8
380 adenosine deaminase deficiency 9.8
381 severe combined immunodeficiency 9.8
382 acquired immunodeficiency syndrome 9.8
383 cerebrovascular disease 9.8
384 mitochondrial metabolism disease 9.8
385 t-cell lymphoblastic leukemia/lymphoma 9.8
386 monoclonal gammopathy of uncertain significance 9.8
387 muscular atrophy 9.8
388 childhood leukemia 9.8
389 placenta disease 9.8
390 hyperthyroidism 9.8
391 septic arthritis 9.8
392 myocarditis 9.8
393 periodontitis 9.8
394 appendicitis 9.8
395 osteoarthritis 9.8
396 lung disease 9.8
397 monocytic leukemia 9.8
398 rubella 9.8
399 fascioliasis 9.8
400 evans' syndrome 9.8
401 hepatopulmonary syndrome 9.8
402 leishmaniasis 9.8
403 cutaneous leishmaniasis 9.8
404 peliosis hepatis 9.8
405 visceral leishmaniasis 9.8
406 tyrosinemia 9.8
407 priapism 9.8
408 hypopituitarism 9.8
409 cholangitis 9.8
410 meningitis 9.8
411 pulmonary embolism 9.8
412 fasciitis 9.8
413 necrotizing fasciitis 9.8
414 yellow fever 9.8
415 biliary tract disease 9.8
416 irritable bowel syndrome 9.8
417 toxoplasmosis 9.8
418 hemophilia 9.8
419 adcy5-related dyskinesia 9.8
420 cartilage-hair hypoplasia - anauxetic dysplasia spectrum disorders 9.8
421 erythropoietic protoporphyria, autosomal recessive 9.8
422 familial porphyria cutanea tarda 9.8
423 mitochondrial disorders 9.8
424 slc39a14 deficiency 9.8
425 x-linked protoporphyria 9.8
426 chronic thromboembolic pulmonary hypertension 9.8
427 engraftment syndrome 9.8
428 inherited bone marrow failure syndromes 9.8
429 leukemia, t-cell, chronic 9.8
430 myelodysplastic syndrome with excess blasts 9.8
431 warfarin syndrome 9.8
432 depression 9.8
433 aneurysm 9.8
434 anoxia 9.8
435 chronic pain 9.8
436 encephalopathy 9.8
437 hypotonia 9.8
438 spasticity 9.8
439 traumatic brain injury 9.8
440 asbestos intoxication 9.8
441 secondary hemophagocytic lymphohistiocytosis 9.8
442 pik3ca-related overgrowth syndrome 9.8
443 acute liver failure 9.8
444 renal dysplasia 9.8
445 premature aging 9.8
446 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.8
447 refractory cytopenia with multilineage dysplasia 9.8
448 chronic hepatic porphyria 9.8

Graphical network of the top 20 diseases related to Rare Hereditary Hemochromatosis:



Diseases related to Rare Hereditary Hemochromatosis

Symptoms & Phenotypes for Rare Hereditary Hemochromatosis

Human phenotypes related to Rare Hereditary Hemochromatosis:

58 31 (showing 14, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 joint stiffness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001387
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
4 joint swelling 58 31 hallmark (90%) Very frequent (99-80%) HP:0001386
5 generalized hyperpigmentation 58 31 hallmark (90%) Very frequent (99-80%) HP:0007440
6 increased serum ferritin 58 31 hallmark (90%) Very frequent (99-80%) HP:0003281
7 hypogonadotropic hypogonadism 31 hallmark (90%) HP:0000044
8 cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001394
9 osteoporosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000939
10 congenital hepatic fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002612
11 cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001638
12 neoplasm of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0002896
13 hypogonadotrophic hypogonadism 58 Very frequent (99-80%)
14 abnormal joint morphology 58 Very frequent (99-80%)

Drugs & Therapeutics for Rare Hereditary Hemochromatosis

Drugs for Rare Hereditary Hemochromatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 176, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
2
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
3
Ledipasvir Approved Phase 4 1256388-51-8 67505836
4
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
5
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
8
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
9
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
10 Dextrans Phase 4
11 Iron-Dextran Complex Phase 4
12 Anticoagulants Phase 4
13 Plasma Substitutes Phase 4
14 Blood Substitutes Phase 4
15 Liver Extracts Phase 4
16 Anti-Infective Agents Phase 4
17 Antiviral Agents Phase 4
18 Lactoferrin Phase 4
19 Ledipasvir, sofosbuvir drug combination Phase 4
20 Antioxidants Phase 4
21 Protective Agents Phase 4
22 Vitamins Phase 4
23 Hypoglycemic Agents Phase 4
24 Antilymphocyte Serum Phase 4
25 Iron Supplement Phase 4
26 Pharmaceutical Solutions Phase 4
27 Iron Chelating Agents Phase 4
28 Chelating Agents Phase 4
29 Immunosuppressive Agents Phase 4
30 Cyclosporins Phase 4
31 Micronutrients Phase 4
32 Trace Elements Phase 4
33 Nutrients Phase 4
34 Central Nervous System Stimulants Phase 4
35
Zinc Approved, Investigational Phase 3 7440-66-6 32051
36
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
37
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
38 Orange Approved Phase 3
39
Amlodipine Approved Phase 3 88150-42-9 2162
40
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
41
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
42
Hydroxyurea Approved Phase 3 127-07-1 3657
43
tannic acid Approved Phase 3 1401-55-4
44
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
45 Hematinics Phase 2, Phase 3
46 Zinc Supplement Phase 3
47 Antihypertensive Agents Phase 3
48 Vasodilator Agents Phase 3
49 Calcium, Dietary Phase 3
50 calcium channel blockers Phase 3
51 Epoetin alfa Phase 2, Phase 3 113427-24-0
52 Ferric Oxide, Saccharated Phase 3
53 Omega 3 Fatty Acid Phase 2, Phase 3
54 Nigella Phase 2, Phase 3
55
Calcium Nutraceutical Phase 3 7440-70-2 271
56
Amphotericin B Approved, Investigational Phase 2 1397-89-3 5280965 14956
57
Ethanol Approved Phase 2 64-17-5 702
58
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
59
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
60
Mycophenolic acid Approved Phase 2 24280-93-1 446541
61
Disulfiram Approved Phase 2 97-77-8 3117
62
Copper Approved, Investigational Phase 2 7440-50-8 27099
63
Deferiprone Approved Phase 2 30652-11-0 2972
64
Ferrous succinate Approved Phase 2 10030-90-7
65
Lactitol Approved, Investigational Phase 2 585-88-6, 585-86-4 493591
66
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
67
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
68
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
69
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
70
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
71
alemtuzumab Approved, Investigational Phase 2 216503-57-0
72
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
73
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
74
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
75
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
76
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
77
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 59-43-8, 70-16-6 1130
78
Trichostatin A Experimental Phase 2 58880-19-6
79 Calciferol Phase 2
80 Ergocalciferols Phase 2
81 Vitamin D2 Phase 2
82 Vitamin B 6 Phase 2
83 Fibrinolytic Agents Phase 2
84 Tissue Plasminogen Activator Phase 2
85 Plasminogen Phase 2
86 Amebicides Phase 2
87 Antiprotozoal Agents Phase 2
88 Antiparasitic Agents Phase 2
89 Liposomal amphotericin B Phase 2
90 Ferrosoferric Oxide Phase 2
91 Parenteral Nutrition Solutions Phase 2
92 Hepcidins Phase 2
93 Thymoglobulin Phase 2
94 Copper Supplement Phase 2
95 Vitamin B Complex Phase 2
96 Thiamin Phase 2
97 Folate Phase 2
98 Vitamin B9 Phase 2
99 Antimetabolites Phase 2
100 Interleukin 1 Receptor Antagonist Protein Phase 2
101 Antirheumatic Agents Phase 2
102 Antifungal Agents Phase 2
103 Anti-Bacterial Agents Phase 2
104 Immunologic Factors Phase 2
105 Antineoplastic Agents, Immunological Phase 2
106 Alkylating Agents Phase 2
107 Antibiotics, Antitubercular Phase 2
108 Ferric Compounds Phase 2
109
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
110
Acetylcysteine Approved, Investigational Phase 1 616-91-1 12035
111
Nifedipine Approved Phase 1 21829-25-4 4485
112
Zinc sulfate Approved, Investigational Phase 1 7733-02-0
113
Azathioprine Approved Phase 1 446-86-6 2265
114 Respiratory System Agents Phase 1
115 Antidotes Phase 1
116 Expectorants Phase 1
117 N-monoacetylcystine Phase 1
118 Tocolytic Agents Phase 1
119 silymarin Phase 1
120 Muromonab-CD3 Phase 1
121 pyruvate Phase 1
122
Pantoprazole Approved 102625-70-7 4679
123
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
124
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 10204 6013
125
Polyestradiol phosphate Approved 28014-46-2
126 Papaya Approved
127
Regadenoson Approved, Investigational 313348-27-5 219024
128
Aspirin Approved, Vet_approved 50-78-2 2244
129
Calcium carbonate Approved, Investigational 471-34-1
130
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
131
Ribavirin Approved 36791-04-5 37542
132
Simeprevir Approved 923604-59-5 66576988
133
Sodium citrate Approved, Investigational 68-04-2
134
Histamine Approved, Investigational 51-45-6 774
135
Ketotifen Approved 34580-13-7, 34580-14-8 3827
136
Acetazolamide Approved, Vet_approved 59-66-5 1986
137
Fludarabine Approved 21679-14-1, 75607-67-9 30751
138
Busulfan Approved, Investigational 55-98-1 2478
139
Mesna Approved, Investigational 3375-50-6 598
140
rituximab Approved 174722-31-7 10201696
141
Cytarabine Approved, Experimental, Investigational